

## Daftar Pustaka

1. Habas K, Nganwuchu C, Shahzad F, Gopalan R, Haque M, Rahman S, et al. Resolution of coronavirus disease 2019 (COVID-19). Vol. 18, Expert Review of Anti-Infective Therapy. Taylor and Francis Ltd.; 2020. p. 1201–11.
2. World Health Organization. Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> - Diakses April 2022
3. Wilder-Smith A, Osman S. Public health emergencies of international concern: A historic overview. Vol. 27, Journal of Travel Medicine. Oxford University Press; 2020. p. 1–10.
4. da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, Farias de Oliveira T, Campos Alcântara R, Monteiro Arnozo G, et al. Clinical manifestations of COVID-19 in the general population: systematic review. *Wien Klin Wochenschr.* 2021 Apr 26;133(7–8):377–82.
5. Clifford CT, Pour TR, Freeman R, Reich DL, Glicksberg BS, Levin MA, et al. Association between COVID-19 diagnosis and presenting chief complaint from New York City triage data. *Am J Emerg Med.* 2021 Aug;46:520–4.
6. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA.* 2020 Apr 7;323(13):1239.
7. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. *Lancet.* 2022;399(10335):1618–24.
8. Maslo C, Friedland R, Toubkin M, Laubscher A, Akaloo T, Kama B. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. *JAMA.* 2022;327(6):583–4.
9. Toharudin T, Pontoh RS, Caraka RE, Zahroh S, Kendogo P, Sijabat N, et al. National vaccination and local intervention impacts on covid-19 cases. *Sustainability (Switzerland).* 2021 Aug 1;13(15).
10. Komite Penanganan COVID-19 dan Pemulihan Ekonomi Nasional. Tujuan Program Vaksinasi Tercapainya Herd Immunity <https://covid19.go.id/p/vaksin/tujuan-program-vaksinasi-tercapainya-herd-immunity> - Diakses April 2022
11. Kemenkeu. Penanggulangan Pandemi COVID-19 Melalui Program Pengadaan Vaksin dan Pelaksanaan Vaksinasi COVID-19. <https://anggaran.kemenkeu.go.id/in/post/penanggulangan-pandemi-covid-19-melalui-program-pengadaan-vaksin-dan-pelaksanaan-vaksinasi-covid-19> - Diakses Mei 2022
12. Komite Penanganan COVID-19 dan Pemulihan Ekonomi Nasional. Situasi COVID-19 di Indonesia (Update per 19 Oktober 2022) <https://covid19.go.id/id/artikel/2022/10/19/situasi-covid-19-di-indonesia-update-19-oktober-2022> - Diakses Oktober 2022
13. Hacısuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *New England Journal of Medicine.* 2021 Jun 10;384(23):2212–8.
14. Centers for Disease Control and Prevention. Vaccine Breakthrough Infections: The Possibility of Getting COVID-19 after Getting Vaccinated.

- <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html> - Diakses Juni 2022
15. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis.* 2022;22(1):43–55.
  16. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat Med.* 2022 May 25;
  17. Bonnie RJ, Stroud C, Breiner H. Investing in the Health and Well-Being of Young Adults. *Investing in the Health and Well-Being of Young Adults.* 2015 Feb 27;1–479.
  18. Guilamo-Ramos V, Benzekri A, Thimm-Kaiser M, Hidalgo A, Perlman DC. Reconsidering Assumptions of Adolescent and Young Adult Severe Acute Respiratory Syndrome Coronavirus 2 Transmission Dynamics. *Clin Infect Dis.* 2021 Jul 30;73(Suppl 2):S146–63.
  19. World Health Organization. Naming the coronavirus disease (COVID-19) and the virus that causes it. [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it) – Diakses November 2022
  20. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. *J Med Virol.* 2020 Apr 1;92(4):418–23.
  21. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. *J Med Virol.* 2020 Jun 1;92(6):548–51.
  22. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? *Clin Microbiol Infect.* 2020 Jun;26(6):729–34.
  23. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.*
  24. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.* 2020;395:565.
  25. Goldsmith CS, Tatti KM, Ksiazek TG, Rollin PE, Comer JA, Lee WW, et al. Ultrastructural Characterization of SARS Coronavirus - Volume 10, Number 2—February 2004 - *Emerging Infectious Diseases journal - CDC.* *Emerg Infect Dis.* 2004;10(2):320–6.
  26. Kumar S, Nyodu R, Maurya VK, Saxena SK, Kumar S, Nyodu · R, et al. Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
  27. Forchette L, Sebastian W, Liu T. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. *Curr Med Sci.* 2021 Dec 1;41(6):1037–51.
  28. World Health Organization. Tracking SARS-CoV-2 variants. <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/> - Diakses Juni 2022
  29. Government Digital Service. Investigation of SARS-CoV-2 variants of concern:technical.<https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201> - Diakses Juni 2022
  30. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science.* 2021;372(6538).
  31. Banerjee A, Lew J, Kroeker A, Baid K, Aftanas P, Nirmalarajah K, et al. Immunogenicity of convalescent and vaccinated sera against clinical isolates of

- ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. *Med.* 2022;3:422-432.e3.
32. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature.* 2021;592(7854):438–43.
  33. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. *Euro Surveill.* 2021;26(16).
  34. Andrew Rambaut. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology – Virological. <https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manauas-preliminary-findings/586> - Diakses Juni 2022
  35. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. *Cell Host Microbe.* 2021;29(5):747-751.e4.
  36. Yang W, Shaman J. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant and implications for vaccination. *J R Soc Interface.* 2022 Jun 6;19(191).
  37. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet.* 2021;397(10293):2461–2.
  38. Gowrisankar A, Priyanka TMC, Banerjee S. Omicron: a mysterious variant of concern. *The European Physical Journal Plus.* 2022 Jan 10;137(1):100.
  39. Centre of Disease Prevention E. Implications of the emergence and spread of the SARS-CoV-2 B.1.1. 529 variant of concern (Omicron) for the EU/EEA. 2021;
  40. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Eurosurveillance.* 2021 Jun 17;26(24):1–6.
  41. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. *JAMA.* 2022 Apr 5;327(13):1286.
  42. World Health Organization . Weekly epidemiological update on COVID-19 - 22 June 2022 <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19--22-june-2022> - Diakses Juni 2022
  43. D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. *Clinical Gastroenterology and Hepatology.* 2020 Jul 1;18(8):1663–72.
  44. Li M, Liang C, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. 2020;
  45. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19). *JAMA.* 2020 Aug 25;324(8):782.
  46. Hu Y, Liang W, Liu L, Li L. Clinical Characteristics of Coronavirus Disease 2019 in China. *n engl j med.* 2020;18:1708–28.
  47. Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine.* 2020 Apr 30;382(18):1708–20.
  48. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med.* 2020 May 5;172(9):577–82.

49. Qin J, You C, Lin Q, Hu T, Yu S, Zhou XH. Estimation of incubation period distribution of COVID-19 using disease onset forward time: A novel cross-sectional and forward follow-up study. *Sci Adv.* 2020 Aug 1;6(33):1202–16.
50. Jansen L, Tegomoh B, Lange K, Showalter K, Figliomeni J, Abdalhamid B, et al. Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster - Nebraska, November-December 2021. *MMWR Morb Mortal Wkly Rep.* 2021 Dec 31;70(5152):1782–4.
51. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Euro Surveill.* 2021 Dec;26(50).
52. Brandal LT, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U, et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Eurosurveillance.* 2021 Dec 16;26(50).
53. Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. *The Lancet.* 2022 Apr;399(10335):1618–24.
54. Zayet S, Kadiane-Oussou NJ, Lepiller Q, Zahra H, Royer PY, Toko L, et al. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster. *Microbes Infect.* 2020 Oct;22(9):481–8.
55. Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. *Cochrane Database of Systematic Reviews.* 2020 Jul 7;
56. Centers of Disease Control and Prevention. Clinical Presentation - Clinical Care Considerations <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-presentation.html> - Diakses Juli 2022
57. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, el Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance - United States, January 22-May 30, 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jun 19;69(24):759–65.
58. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious Diseases.* 2020 May;94:91–5.
59. Tenforde MW, Billig Rose E, Lindsell CJ, Shapiro NI, Files DC, Gibbs KW, et al. Characteristics of Adult Outpatients and Inpatients with COVID-19 — 11 Academic Medical Centers, United States, March–May 2020. *MMWR Morb Mortal Wkly Rep.* 2022 Jul 3;69(26):841–6.
60. Nasiri N, Sharifi H, Bazrafshan A, Noori A, Karamouzian M, Sharifi A. Ocular Manifestations of COVID-19: A Systematic Review and Meta-analysis. *J Ophthalmic Vis Res.* 2021 Jan 20;
61. Genovese G, Moltrasio C, Berti E, Marzano AV. Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives. *Dermatology.* 2021;237(1):1–12.
62. National Institute of Health. Clinical Spectrum COVID-19 Treatment Guidelines. <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/> - Diakses Juni 2022
63. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. 2020;
64. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a

- Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Apr 3;69(13):377–81.
65. Sheehan MM, Reddy AJ, Rothberg MB. Reinfection Rates Among Patients Who Previously Tested Positive for Coronavirus Disease 2019: A Retrospective Cohort Study. *Clin Infect Dis.* 2021 Nov 15;73(10):1882–6.
  66. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic A Systematic Review Background: Asymptomatic infection seems to be a nota. 2021;
  67. Huespe I, Carboni Bisso I, di Stefano S, Terrasa S, Gemelli NA, las Heras M. COVID-19 Severity Index: A predictive score for hospitalized patients. *Med Intensiva.* 2020 Dec 29;46(2):98–101.
  68. Kementerian Kesehatan RI. Pedoman Pencegahan dan Pengendalian Coronavirus Disease (COVID-19. <https://covid19.go.id/id/p/protokol/pedoman-pencegahan-dan-pengendalian-coronavirus-disease-covid-19-revisi-ke-5> - Diakses Oktober 2022
  69. Burhan E, Dwi Susanto A, Isbaniah F, Aman Nasution S, Ginanjar E, Wicaksono Pitoyo C, et al. PEDOMAN TATALAKSANA COVID-19 Edisi 3 TIM EDITOR Perhimpunan Dokter Paru Indonesia (PDPI) Perhimpunan Dokter Spesialis Kardiovaskular Indonesia (PERKI) Perhimpunan Dokter Spesialis Penyakit Dalam Indonesia (PAPDI) Perhimpunan Dokter Anestesiologi dan Terapi Intensif Indonesia (PERDATIN) Ikatan Dokter Anak Indonesia (IDAI). 2020.
  70. Wang J, Kaperak C, Sato T, Sakuraba A. COVID-19 reinfection: a rapid systematic review of case reports and case series. *Journal of Investigative Medicine.* 2021 Aug;69(6):1253–5.
  71. Centers of Disease Control and Prevention. Reinfection - Clinical Care Considerations. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-reinfection.html> - Diakses Juli 2022
  72. Ministry of Health New Zealand. COVID-19 reinfection advice. <https://www.health.govt.nz/news-media/news-items/covid-19-reinfection-advice-updated> - Diakses Juli 2022
  73. Centers of Disease Control and Prevention. COVID-19 after Vaccination: Possible Breakthrough Infection. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html> - Diakses Juli 2022
  74. Birhane M, Bressler S, Chang G, Clark T, Dorough L, Fischer M, et al. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021. *MMWR Morb Mortal Wkly Rep.* 2021 May 28;70(21):792–3.
  75. Yek C, Warner S, Wiltz JL, Sun J, Adjei S, Mancera A, et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged  $\geq 18$  Years Who Completed a Primary COVID-19 Vaccination Series-465 Health Care Facilities, United States, December 2020-October 2021.
  76. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis.* 2022;22(1):43–55.
  77. Isbaniah F, Saputro D, Sitompul P, Manalu R, Setyawaty V, Kandun I, et al. Pedoman Kesiapsiagaan Menghadapi Virus corona Disease (COVID-19). Kementerian Kesehatan RI. 2020.
  78. Dawson P, Rabold EM, Laws RL, Connors EE, Gharpure R, Yin S, et al. Loss of Taste and Smell as Distinguishing Symptoms of Coronavirus Disease 2019. *Clinical Infectious Diseases.* 2021 Feb 16;72(4):682–5.

79. Cohen PA, Hall LE, John JN, Rapoport AB. The Early Natural History of SARS-CoV-2 Infection: Clinical Observations From an Urban, Ambulatory COVID-19 Clinic. *Mayo Clin Proc.* 2020 Jun;95(6):1124–6.
80. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, et al. Diagnostic Testing for Severe Acute Respiratory Syndrome–Related Coronavirus 2. *Ann Intern Med.* 2020 Jun 2;172(11):726–34.
81. Weissleder R, Lee H, Ko J, Pittet MJ. COVID-19 diagnostics in context. *Sci Transl Med.* 2020 Jun 3;12(546).
82. Elsevier. Vaccination. In: *Primer to the Immune Response.* Elsevier; 2014. p. 333–75.
83. Bhardwaj S. Vaccines. In: *Pharmaceutical Medicine and Translational Clinical Research.* Elsevier Inc.; 2017. p. 341–53.
84. World Health Organization. Guidelines on clinical evaluation of vaccines regulatory expectations. <https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9> - Diakses November 2022
85. World Health Organization. Guidelines on clinical evaluation of vaccines regulatory expectations. <https://www.who.int/publications/m/item/WHO-TRS-1004-web-annex-9> - Diakses November 2022
86. Centers of Disease Control and Prevention. Summary of Recent Changes Key Points. <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html#previous> – Diakses Agustus 2022
87. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. *Lancet.* 2021;398(10296):213–22.
88. Fadlyana E, Rusmil K, Tarigan R, Rahmadi AR, Prodjosoeowojo S, Sofiatin Y, et al. A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia. *Vaccine.* 2021;39(44):6520–8.
89. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *N Engl J Med.* 2021;385(10):875–84.
90. Han B, Li M, Wu Z, Zhao Y, Li Q, Biotech S, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis.* 2021;21:1645–53.
91. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet.* 2021;397(10269):99–111.
92. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. *N Engl J Med.* 2021;385(25):2348–60.
93. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet.* 2020;396(10249):467–78.
94. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet.* 2020;396(10249):467–78.
95. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-

- CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*. 2021;397(10269):99–111.
96. Pottegård A, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ*. 2021;373:n1114.
  97. Baden LR, el Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*. 2021 Feb 4;384(5):403–16.
  98. el Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. *New England Journal of Medicine*. 2021 Nov 4;385(19):1774–85.
  99. Jackson LA, Anderson EJ, Roupheal NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *New England Journal of Medicine*. 2020 Nov 12;383(20):1920–31.
  100. Anderson EJ, Roupheal NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *New England Journal of Medicine*. 2020 Dec 17;383(25):2427–38.
  101. Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *New England Journal of Medicine*. 2021 Dec 9;385(24):2241–51.
  102. Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *New England Journal of Medicine*. 2021 Jun 10;384(23):2259–61.
  103. Vasan A, Kenyon CC, Feudtner C, Fiks AG, Venkataramani AS. Association of WIC Participation and Electronic Benefits Transfer Implementation. *JAMA Pediatr*. 2021 Jun 1;175(6):609–16.
  104. Richards NE, Keshavarz B, Workman LJ, Nelson MR, Platts-Mills TAE, Wilson JM. Comparison of SARS-CoV-2 Antibody Response by Age among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine. Vol. 4, *JAMA Network Open*. American Medical Association; 2021.
  105. Fda, Cber. Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Briefing Document - FDA. 2020.
  106. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mrna-based covid-19 vaccines. Vol. 325, *JAMA - Journal of the American Medical Association*. American Medical Association; 2021. p. 2201–2.
  107. Shimabukuro T. COVID-19 vaccine safety update, Advisory Committee on Immunization Practices (ACIP) meeting, January 27, 2021.
  108. Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007 Aug 1;25(31):5675–84.
  109. Sangli S, Virani A, Cheronis N, Vannatter B, Minich C, Noronha S, et al. Thrombosis with thrombocytopenia after the messenger rna-1273 vaccine. Vol. 174, *Annals of Internal Medicine*. American College of Physicians; 2021. p. 1480–2.
  110. Xia S, Wang Y, Zhang W, Xie Z, You W, Huang L, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis*. 2020;21:39–51.
  111. al Kaabi N, Zhang Y, Xia S, Yang Y, al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA*. 2021;326(1):35–45.

112. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*. 2020 Dec 31;383(27):2603–15.
113. Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *New England Journal of Medicine*. 2021 Jul 15;385(3):239–50.
114. U.S. Food and Drug Administration. Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) for 5 through 11 years of age. <https://www.fda.gov/media/153714/download> - Diakses April 2022
115. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. *New England Journal of Medicine*. 2021 Nov 4;385(19):1761–73.
116. U.S. Food and Drug Administration. Briefing Document. Pfizer-BioNTech COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting, December 10, 2020. <https://www.fda.gov/media/144245/download> - Diakses Mei 2022
117. Gee J, Paige Marquez :, Su J, Calvert GM, Liu R, Myers T, et al. MMWR, First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021. 2020.
118. COVID-19 vaccine safety update, Advisory Committee on Immunization Practices (ACIP) meeting, January 27, 2021.
119. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. *N Engl J Med*. 2022 Feb 10;386(6):531–43.
120. Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *N Engl J Med*. 2021;385(13):1172–83.
121. Logunov DY, Dolzhikova I v, Zubkova O v, Tikhvatullin AI, Shcheblyakov D v, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. *Lancet*. 2020;396(10255):887–97.
122. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. *New England Journal of Medicine*. 2021 Jun 10;384(23):2187–201.
123. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. *N Engl J Med*. 2022;386(9):847–60.
124. Shay DK, Gee J, Su JR, Myers TR, Marquez P, Liu R, et al. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021. *MMWR Morb Mortal Wkly Rep*. 2021 May 7;70(18):680–4.
125. Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, et al. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination — Five U.S. Mass Vaccination Sites, April 2021. *MMWR Morb Mortal Wkly Rep*. 2021 May 7;70(18):685–8.
126. Takuva S, Takalani A, Garrett N, Goga A, Peter J, Louw V, et al. Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. *N Engl J Med*. 2021;385(6):570–1.
127. Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*. 2020 Aug 15;396(10249):479–88.



128. Halperin SA, Ye L, MacKinnon-Cameron D, Smith B, Cahn PE, Ruiz-Palacios GM, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. *Lancet*. 2022 Jan 15;399(10321):237–48.
129. Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. *Lancet Infect Dis*. 2021 Aug 1;21(8):1107–19.
130. Irfan O, Li J, Tang K, Wang Z, Bhutta ZA. Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: A systematic review and meta-analysis. *J Glob Health*. 2021;11:05013.
131. Livingston EH. Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines. *JAMA*. 2021 Mar 2;325(9):898.
132. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. *Nat Med*. 2022 Apr;28(4):831–7.
133. Zhang X bin, Yang SJ, Lin Y, Chen LL, Zhuang YL, Zeng HQ. Clinical Characteristics of COVID-19 Patients' Postvaccination. *Viral Immunol*. 2022 Apr 1;35(3):236.
134. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet Infect Dis*. 2022 Jan;22(1):43–55.
135. Abdulrazaq MK, al Redha Jebur AA, Ali Hamdan BJ, Ibrahim A khalid. Frequency and Clinical Characteristics of Breakthrough Cases Post COVID-19 Vaccine and Predictive Risk Factors in College Students. *medRxiv*. 2023;2023.01.20.23284814.

